Release of Danger-Associated Molecular Patterns following Chemotherapy Does Not Induce Immunoparalysis in Leukemia Patients

Chemotherapy may result in the release of danger-associated molecular patterns (DAMPs), which can cause immunoparalysis (deactivation of the immune system). We investigated DAMPs following chemotherapy and their relationship with markers of immunoparalysis in leukemia patients. In 6 patients with acute myeloid leukemia or myelodysplastic syndrome and 12 healthy subjects, DAMPs, cytokines, and markers of immunoparalysis were determined before and during the first week after chemotherapy initiation. In the patients, plasma levels of nuclear DNA (a marker of general DAMP release) were profoundly increased before chemotherapy and further increased 4-6 h afterwards, while the specific DAMP mitochondrial DNA showed only a trend towards increase. Circulating cytokine levels did not change following chemotherapy. Leukocyte cytokine production capacity and HLA-DR expression were similar in patients and healthy controls until day 4 when leukocytes were found to be virtually absent. In conclusion, in the early phase following chemotherapy in leukemia patients, increased DAMP release does not induce immunoparalysis.

[1]  Asim Khwaja,et al.  Acute myeloid leukaemia , 2016, Nature Reviews Disease Primers.

[2]  J. G. van der Hoeven,et al.  The Involvement of Danger-Associated Molecular Patterns in the Development of Immunoparalysis in Cardiac Arrest Patients , 2015, Critical care medicine.

[3]  B. Baban,et al.  Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats. , 2015, Cardiovascular research.

[4]  F. Sweep,et al.  Voluntary activation of the sympathetic nervous system and attenuation of the innate immune response in humans , 2014, Proceedings of the National Academy of Sciences.

[5]  B. Söderquist,et al.  Preliminary results in quantitation of HLA-DRA by real-time PCR: a promising approach to identify immunosuppression in sepsis , 2013, Critical Care.

[6]  L. Koenderman,et al.  Kinetics of the Innate Immune Response After Trauma: Implications for the Development of Late Onset Sepsis , 2013, Shock.

[7]  M. Netea,et al.  Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? , 2013, American journal of respiratory and critical care medicine.

[8]  L. Moldawer,et al.  DAMPs, PAMPs, and the origins of SIRS in bacterial sepsis. , 2013, Shock.

[9]  J. G. van der Hoeven,et al.  The effects of brain injury on heart rate variability and the innate immune response in critically ill patients. , 2012, Journal of neurotrauma.

[10]  H. Freeze,et al.  Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. , 2009, Neoplasia.

[11]  T. Alonzo,et al.  Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. , 2007, Blood.

[12]  P. Matzinger.  The Danger Model: A Renewed Sense of Self , 2002, Science.

[13]  F. Appelbaum,et al.  Haematopoietic cell transplantation as immunotherapy , 2001, Nature.

[14]  J. Child,et al.  Defective neutrophil function and microbicidal mechanisms in the myelodysplastic disorders. , 1983, Journal of clinical pathology.

[15]  Y. S. Sathe,et al.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. , 1966, Annals of internal medicine.